Chapter 3 – MAT Myth Busters
MAT Myth Busters
COURSE DESCRIPTION
The term opioid use disorder (OUD) is used for those suffering from the disease of addiction related to opioids. Nearly 80% of Americans with OUD are not receiving appropriate care. While access to office-based addiction treatment has increased in recent years, distribution of medication-assisted treatment (MAT) has been slowing. MAT is very effective and can save lives, however, physicians have misconceptions about the OUD patient population, MAT's effectiveness, and how it works. In this session, addiction expert, Dr. Lee Radosh, will dispel some of the myths around MAT and explain why you should be offering this treatment to your patients with OUD.
INSTRUCTIONS
- Click "Begin Course" to start.
- Read each page of the infographic
- Answer the question at the bottom of each page to advance to the next page
- When you have completed all 4 pages, complete the post-test and evaluation
- You must score 100% on the post-test to receive credit
- Physicians, claim your CME and print out your certificate
- Residents, course completion will be logged to your transcript
ACCREDITATION STATEMENT
AMA: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the New Jersey of Academy of Family Physicians. The New Jersey Academy of Family Physicians is accredited by the ACCME to provide continuing medical education for physicians.
The New Jersey Academy of Family Physicians designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
LEARNING OBJECTIVES
At the end of this presentation, attendees will be able to:
- List common myths about MAT and patients with OUD, and explain why these myths are not barriers to providing MAT in your practice
- Recognize patients already within your practice who may have or be at risk for developing OUD
- Apply simple, focused, evidence-based interventions when OUD is suspected, including delineating among MAT choices
DISLOSURES
The following individuals have no relevant financial relationships with ineligible companies to disclose:
Planners/Reviewers:
Angie Halaja-Henriques
Sue Hockenberry, PCMH CCE
Theresa J. Barrett, PhD, CMP, CAE
Authors:
Indra Cidambi, MD
Lee Radosh, MD, FAAFP
During this presentation Dr. Radosh will mention how buprenorphine can be used for chronic pain; some buprenorphine formulations are not FDA-approved for pain.